Table 3.
Variables | Recurrence (n = 16) | Fluctuation (n = 7) | Maintenance (n = 12) |
Statistic | |
---|---|---|---|---|---|
N (%) | N(%) | N (%) | χ2 | p | |
Male a | 4(35.0%) | 2(28.6%) | 6(50.0%) | 1.982 | 0.424 |
Psychotic symptoms | 2(12.5%) | 0(0.0%) | 3(25.0%) | 1.895 | 0.477 |
Drinking a | 2(12.5%) | 0(0.0%) | 0(0.0%) | 1.720 | 0.677 |
Experience of child-parent separation | 11(68.8%) | 3(42.9%) | 7(58.3%) | 1.436 | 0.492 |
Treatment regimens | 4.353 | 0.369 | |||
aiTBS | 4(25.0%) | 3(42.9%) | 1(8.3%) | ||
iTBS | 4(25.0%) | 1(14.3%) | 6(50.0%) | ||
Sham | 8(50.0%) | 3(42.9%) | 5(41.7%) | ||
Antidepressanta | 11(68.8%) | 6(85.7%) | 7(58.3%) | 1.439 | 0.507 |
Antipsychotic | 6(37.5%) | 2(28.6%) | 2(16.7%) | 1.466 | 0.561 |
Benzodiazepine | 6(37.5%) | 4(57.1%) | 1(8.3%) | 5.387 | 0.079 |
Mean ± SD | Mean ± SD | Mean ± SD | F/χ2 | p | |
Age (years) | 14.56 ± 1.97 | 15.00 ± 2.00 | 17.33 ± 3.20 | 4.587 | 0.012 |
Education (years) | 9.06 ± 1.84 | 9.29 ± 2.43 | 11.08 ± 2.61 | 3.008 | 0.064 |
Disease duration (months) b | 20.94 ± 14.04 | 20.43 ± 16.29 | 29.33 ± 43.46 | 0.154 | 0.926 |
MT(%) | 54.06 ± 3.97 | 55.57 ± 2.44 | 51.67 ± 5.30 | 2.074 | 0.142 |
Fluoxetine equivalent (mg/day) b |
44.28 ± 83.16 | 21.43 ± 49.72 | 11.11 ± 29.59 | 1.588 | 0.452 |
Chlorpromazine equivalent (mg/day) b | 18.01 ± 16.30 | 17.90 ± 12.93 | 11.48 ± 10.34 | 1.402 | 0.496 |
HAMD-17 | 23.38 ± 5.60 | 24.86 ± 5.94 | 22.61 ± 6.21 | 0.359 | 0.701 |
HAMA | 23.57 ± 8.65 | 21.71 ± 6.85 | 21.50 ± 6.30 | 0.701 | 0.503 |
GAF | 47.50 ± 9.31 | 50.71 ± 5.36 | 49.17 ± 6.69 | 0.441 | 0.648 |
NSSI-behaviorb | 11.00 ± 8.76 | 6.44 ± 3.71 | 7.97 ± 7.93 | 1.470 | 0.479 |
NSSI-function b | 30.56 ± 15.39 | 22.68 ± 9.73 | 27.96 ± 11.02 | 2.024 | 0.364 |
Abbreviations: aiTBS accelerated intermittent Theta Burst Stimulation, MT Motor Threshold, HAMD-17 17-item Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale, GAF Global Assessment of Function, NSSI Non-suicidal Self-Injury
aFisher exact test
bKruskal-Wallis test